{"id":32465,"date":"2023-10-10T07:30:00","date_gmt":"2023-10-10T05:30:00","guid":{"rendered":"https:\/\/www.transgene.com\/?p=32465"},"modified":"2026-07-09T14:46:26","modified_gmt":"2026-07-09T12:46:26","slug":"transgene-et-bioinvent-un-premier-patient-traite-dans-la-partie-b-de-lessai-de-phase-i-evaluant-le-virus-oncolytique-bt-001-en-combinaison-avec-keytrudapembrolizumab","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/transgene-et-bioinvent-un-premier-patient-traite-dans-la-partie-b-de-lessai-de-phase-i-evaluant-le-virus-oncolytique-bt-001-en-combinaison-avec-keytrudapembrolizumab\/","title":{"rendered":"Transgene et BioInvent &#8211; Un premier patient trait\u00e9 dans la partie B de l&rsquo;essai de Phase I \u00e9valuant le virus oncolytique BT-001 en combinaison avec KEYTRUDA\u00ae(pembrolizumab)"},"content":{"rendered":"\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n\n\n\n<p class=\"eplus-DVrMbh\"><a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20231010-Transgene_BioInvent_BT-001_Phase_Ib_1erpatient_inclus_FR_VFinal.pdf\">Transgene et BioInvent &#8211; premier patient trait\u00e9 dans la partie B de la phase I<\/a><\/p>\n\n\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; &nbsp; Transgene et BioInvent &#8211; premier patient trait\u00e9 dans la partie B de la phase I<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[164,91,11,128],"tags":[],"class_list":["post-32465","post","type-post","status-publish","format-standard","hentry","category-164","category-bt-001-fr","category-press-release-fr","category-dates","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"nh","author_link":"https:\/\/www.transgene.com\/fr\/author\/nh\/"},"uagb_comment_info":0,"uagb_excerpt":"&nbsp; &nbsp; Transgene et BioInvent &#8211; premier patient trait\u00e9 dans la partie B de la phase I","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/32465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=32465"}],"version-history":[{"count":1,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/32465\/revisions"}],"predecessor-version":[{"id":41489,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/32465\/revisions\/41489"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=32465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=32465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=32465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}